Table 1.
Pharmacologic features of luspatercept
| Parameter | Details |
|---|---|
| Class | Antianemic drug, immunoglobulin Fc fragments, recombinant fusion protein |
| ATC code | WHO: B03XA06 (other antianemic preparations); EphMRA: B3X (other antianemic products) |
| Additional names | ACE-536, Reblozyl |
| Route of administration | Subcutaneously once every 21 days |
| Pharmacodynamics | SMAD2/3 ligand GDF11 and activating B signaling inhibition |
| Pharmacokinetics | Mean steady-state Cmax, 8.17 μg/mL; AUC, 126 days⋅μg/mL after administration at 1 mg/kg in patients with beta-thalassaemia |
| AEs | Frequent: headache, diarrhea, dizziness, bone pain, arthralgia, fatigue, abdominal pain; occasional: nausea, hyperuricemia, viral infection; rare: deep vein thrombosis, cerebrovascular accident |
Reprinted by permission from: Springer, Drugs. Markham, A. Luspatercept: First Approval. Drugs 80, 85-90 (2020). © 2020.43
ATC, Anatomical Therapeutic Chemical; AUC, area under the curve; EphMRA, European Pharmaceutical Market Research Association; WHO, World Health Organization.